KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas

A. Gloghini, A. Rizzo, I. Zanette, B. Canal, G. Rupolo, P. Bassi, A. Carbone

Research output: Contribution to journalArticle

Abstract

Expression of KP1/CD68 macrophage-associated antigen in a series of 840 selected malignant neoplasms, including immunomorphologically characterized cases of non-Hodgkin's lymphoma (NHL) (434), Hodgkin's disease (HD) (115), soft tissue sarcoma (147), carcinoma (49), and other tumors (95), was examined. KP1 expression was detected in a significant number of NHLs (107 of 434; 24.7%), most of them (65 of 107; 60.7%) of the diffuse small cell subtype. Only 14 of the 155 large cell lymphomas, compared to 10 of the 51 Ki-1/CD30+ anaplastic large cell (ALC) lymphomas examined, were KP1 positive. Conversely, none of the T-lineage NHL-other than Ki-1/CD30+ ALC lymphomas-or the HD cases tested was labeled by KP1 antibody. Among the other neoplasms tested, KP1 was reactive with a variable proportion of cases of malignant fibrous histiocytoma (19 of 24; 79.2%), malignant schwannoma (8 of 22; 36.4%), liposarcoma (3 of 9; 33.3%), leiomyosarcoma (8 of 37; 21.6%), cutaneous or metastatic melanoma (51 of 73; 69.9%), and renal cell carcinoma (3 of 5; 60%). These results indicate that KP1 shows a relatively wide spectrum of immunoreactivity with malignant neoplasms of presumed non- histiocyte origin, thus arguing against its expected specificity and high value in diagnostic pathology. Although the significance of KP1 expression by some subsets of NHLs remains to be elucidated, its close association with B- cell NHLs, mostly of the diffuse small cell type, should stimulate further pathologic and clinical investigations.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume103
Issue number4
Publication statusPublished - 1995

Fingerprint

Sarcoma
Lymphoma
Carcinoma
Anaplastic Large-Cell Lymphoma
Hodgkin Disease
Non-Hodgkin's Lymphoma
Neoplasms
Malignant Fibrous Histiocytoma
Liposarcoma
Histiocytes
Leiomyosarcoma
Neurilemmoma
Renal Cell Carcinoma
Melanoma
B-Lymphocytes
Macrophages
Pathology
Antigens
Skin
Antibodies

Keywords

  • CD68
  • Immunohistochemistry
  • KP1 monoclonal antibody
  • Malignant tumors
  • Non- Hodgkin's lymphomas
  • Sarcomas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Gloghini, A., Rizzo, A., Zanette, I., Canal, B., Rupolo, G., Bassi, P., & Carbone, A. (1995). KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. American Journal of Clinical Pathology, 103(4), 425-431.

KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. / Gloghini, A.; Rizzo, A.; Zanette, I.; Canal, B.; Rupolo, G.; Bassi, P.; Carbone, A.

In: American Journal of Clinical Pathology, Vol. 103, No. 4, 1995, p. 425-431.

Research output: Contribution to journalArticle

Gloghini, A, Rizzo, A, Zanette, I, Canal, B, Rupolo, G, Bassi, P & Carbone, A 1995, 'KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas', American Journal of Clinical Pathology, vol. 103, no. 4, pp. 425-431.
Gloghini, A. ; Rizzo, A. ; Zanette, I. ; Canal, B. ; Rupolo, G. ; Bassi, P. ; Carbone, A. / KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas. In: American Journal of Clinical Pathology. 1995 ; Vol. 103, No. 4. pp. 425-431.
@article{0cb44863ad0f418b951d5d09fada65f7,
title = "KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas",
abstract = "Expression of KP1/CD68 macrophage-associated antigen in a series of 840 selected malignant neoplasms, including immunomorphologically characterized cases of non-Hodgkin's lymphoma (NHL) (434), Hodgkin's disease (HD) (115), soft tissue sarcoma (147), carcinoma (49), and other tumors (95), was examined. KP1 expression was detected in a significant number of NHLs (107 of 434; 24.7{\%}), most of them (65 of 107; 60.7{\%}) of the diffuse small cell subtype. Only 14 of the 155 large cell lymphomas, compared to 10 of the 51 Ki-1/CD30+ anaplastic large cell (ALC) lymphomas examined, were KP1 positive. Conversely, none of the T-lineage NHL-other than Ki-1/CD30+ ALC lymphomas-or the HD cases tested was labeled by KP1 antibody. Among the other neoplasms tested, KP1 was reactive with a variable proportion of cases of malignant fibrous histiocytoma (19 of 24; 79.2{\%}), malignant schwannoma (8 of 22; 36.4{\%}), liposarcoma (3 of 9; 33.3{\%}), leiomyosarcoma (8 of 37; 21.6{\%}), cutaneous or metastatic melanoma (51 of 73; 69.9{\%}), and renal cell carcinoma (3 of 5; 60{\%}). These results indicate that KP1 shows a relatively wide spectrum of immunoreactivity with malignant neoplasms of presumed non- histiocyte origin, thus arguing against its expected specificity and high value in diagnostic pathology. Although the significance of KP1 expression by some subsets of NHLs remains to be elucidated, its close association with B- cell NHLs, mostly of the diffuse small cell type, should stimulate further pathologic and clinical investigations.",
keywords = "CD68, Immunohistochemistry, KP1 monoclonal antibody, Malignant tumors, Non- Hodgkin's lymphomas, Sarcomas",
author = "A. Gloghini and A. Rizzo and I. Zanette and B. Canal and G. Rupolo and P. Bassi and A. Carbone",
year = "1995",
language = "English",
volume = "103",
pages = "425--431",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - KP1/CD68 expression in malignant neoplasms including lymphomas, sarcomas, and carcinomas

AU - Gloghini, A.

AU - Rizzo, A.

AU - Zanette, I.

AU - Canal, B.

AU - Rupolo, G.

AU - Bassi, P.

AU - Carbone, A.

PY - 1995

Y1 - 1995

N2 - Expression of KP1/CD68 macrophage-associated antigen in a series of 840 selected malignant neoplasms, including immunomorphologically characterized cases of non-Hodgkin's lymphoma (NHL) (434), Hodgkin's disease (HD) (115), soft tissue sarcoma (147), carcinoma (49), and other tumors (95), was examined. KP1 expression was detected in a significant number of NHLs (107 of 434; 24.7%), most of them (65 of 107; 60.7%) of the diffuse small cell subtype. Only 14 of the 155 large cell lymphomas, compared to 10 of the 51 Ki-1/CD30+ anaplastic large cell (ALC) lymphomas examined, were KP1 positive. Conversely, none of the T-lineage NHL-other than Ki-1/CD30+ ALC lymphomas-or the HD cases tested was labeled by KP1 antibody. Among the other neoplasms tested, KP1 was reactive with a variable proportion of cases of malignant fibrous histiocytoma (19 of 24; 79.2%), malignant schwannoma (8 of 22; 36.4%), liposarcoma (3 of 9; 33.3%), leiomyosarcoma (8 of 37; 21.6%), cutaneous or metastatic melanoma (51 of 73; 69.9%), and renal cell carcinoma (3 of 5; 60%). These results indicate that KP1 shows a relatively wide spectrum of immunoreactivity with malignant neoplasms of presumed non- histiocyte origin, thus arguing against its expected specificity and high value in diagnostic pathology. Although the significance of KP1 expression by some subsets of NHLs remains to be elucidated, its close association with B- cell NHLs, mostly of the diffuse small cell type, should stimulate further pathologic and clinical investigations.

AB - Expression of KP1/CD68 macrophage-associated antigen in a series of 840 selected malignant neoplasms, including immunomorphologically characterized cases of non-Hodgkin's lymphoma (NHL) (434), Hodgkin's disease (HD) (115), soft tissue sarcoma (147), carcinoma (49), and other tumors (95), was examined. KP1 expression was detected in a significant number of NHLs (107 of 434; 24.7%), most of them (65 of 107; 60.7%) of the diffuse small cell subtype. Only 14 of the 155 large cell lymphomas, compared to 10 of the 51 Ki-1/CD30+ anaplastic large cell (ALC) lymphomas examined, were KP1 positive. Conversely, none of the T-lineage NHL-other than Ki-1/CD30+ ALC lymphomas-or the HD cases tested was labeled by KP1 antibody. Among the other neoplasms tested, KP1 was reactive with a variable proportion of cases of malignant fibrous histiocytoma (19 of 24; 79.2%), malignant schwannoma (8 of 22; 36.4%), liposarcoma (3 of 9; 33.3%), leiomyosarcoma (8 of 37; 21.6%), cutaneous or metastatic melanoma (51 of 73; 69.9%), and renal cell carcinoma (3 of 5; 60%). These results indicate that KP1 shows a relatively wide spectrum of immunoreactivity with malignant neoplasms of presumed non- histiocyte origin, thus arguing against its expected specificity and high value in diagnostic pathology. Although the significance of KP1 expression by some subsets of NHLs remains to be elucidated, its close association with B- cell NHLs, mostly of the diffuse small cell type, should stimulate further pathologic and clinical investigations.

KW - CD68

KW - Immunohistochemistry

KW - KP1 monoclonal antibody

KW - Malignant tumors

KW - Non- Hodgkin's lymphomas

KW - Sarcomas

UR - http://www.scopus.com/inward/record.url?scp=0028950601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028950601&partnerID=8YFLogxK

M3 - Article

C2 - 7726138

AN - SCOPUS:0028950601

VL - 103

SP - 425

EP - 431

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -